TY  - JOUR
AU  - Simon, Iris
AU  - Perales, Sonia
AU  - Casado-Medina, Laura
AU  - Rodríguez-Martínez, Alba
AU  - Garrido-Navas, Maria Del Carmen
AU  - Puche-Sanz, Ignacio
AU  - Diaz-Mochon, Juan J
AU  - Alaminos, Clara
AU  - Lupiañez, Pablo
AU  - Lorente, Jose A
AU  - Serrano, María J
AU  - Real, Pedro J
PY  - 2021
DO  - 10.3390/cancers13061483
SN  - 2072-6694
UR  - https://hdl.handle.net/10668/28438
T2  - Cancers
AB  - Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although ADT is initially effective, a subsequent castration resistance status...
LA  - en
KW  - AR-V7
KW  - AR-V9
KW  - Novel hormonal agents
KW  - abiraterone
KW  - androgen receptor
KW  - castration resistant prostate cancer
KW  - cross-resistance
KW  - enzalutamide
KW  - transcriptional regulation
TI  - Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation.
TY  - research article
VL  - 13
ER  -